These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 24116948

  • 1. In vitro and in vivo anti-tumour effects of MPT0B014, a novel derivative aroylquinoline, and in combination with erlotinib in human non-small-cell lung cancer cells.
    Tsai AC, Pai HC, Wang CY, Liou JP, Teng CM, Wang JC, Pan SL.
    Br J Pharmacol; 2014 Jan; 171(1):122-33. PubMed ID: 24116948
    [Abstract] [Full Text] [Related]

  • 2. Orally active microtubule-targeting agent, MPT0B271, for the treatment of human non-small cell lung cancer, alone and in combination with erlotinib.
    Tsai AC, Wang CY, Liou JP, Pai HC, Hsiao CJ, Chang JY, Wang JC, Teng CM, Pan SL.
    Cell Death Dis; 2014 Apr 10; 5(4):e1162. PubMed ID: 24722287
    [Abstract] [Full Text] [Related]

  • 3. Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer.
    Wang M, Zhao J, Zhang LM, Li H, Yu JP, Ren XB, Wang CL.
    J Cancer Res Clin Oncol; 2012 Dec 10; 138(12):2069-77. PubMed ID: 22821179
    [Abstract] [Full Text] [Related]

  • 4. Acetyl-macrocalin B, an ent-kaurane diterpenoid, initiates apoptosis through the ROS-p38-caspase 9-dependent pathway and induces G2/M phase arrest via the Chk1/2-Cdc25C-Cdc2/cyclin B axis in non-small cell lung cancer.
    Wang JN, Zhang ZR, Che Y, Yuan ZY, Lu ZL, Li Y, Li N, Wan J, Sun HD, Sun N, Puno PT, He J.
    Cancer Biol Ther; 2018 Jul 03; 19(7):609-621. PubMed ID: 29565730
    [Abstract] [Full Text] [Related]

  • 5. JAK2 inhibitor TG101348 overcomes erlotinib-resistance in non-small cell lung carcinoma cells with mutated EGF receptor.
    Zhang FQ, Yang WT, Duan SZ, Xia YC, Zhu RY, Chen YB.
    Oncotarget; 2015 Jun 10; 6(16):14329-43. PubMed ID: 25869210
    [Abstract] [Full Text] [Related]

  • 6. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
    Howe GA, Xiao B, Zhao H, Al-Zahrani KN, Hasim MS, Villeneuve J, Sekhon HS, Goss GD, Sabourin LA, Dimitroulakos J, Addison CL.
    PLoS One; 2016 Jun 10; 11(3):e0150567. PubMed ID: 26962872
    [Abstract] [Full Text] [Related]

  • 7. Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts.
    Iwai T, Moriya Y, Shirane M, Fujimoto-Ouchi K, Mori K.
    Oncol Rep; 2012 Apr 10; 27(4):923-8. PubMed ID: 22209766
    [Abstract] [Full Text] [Related]

  • 8. Antitumor activity of AZ64 via G2/M arrest in non-small cell lung cancer.
    Xue Y, Ren H, Xiao W, Chu Z, Lee JJ, Mao L.
    Int J Oncol; 2012 Nov 10; 41(5):1798-808. PubMed ID: 22948297
    [Abstract] [Full Text] [Related]

  • 9. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
    Wang Y, Singh R, Wang L, Nilsson M, Goonatilake R, Tong P, Li L, Giri U, Villalobos P, Mino B, Rodriguez-Canales J, Wistuba I, Wang J, Heymach JV, Johnson FM.
    Oncotarget; 2016 Jul 26; 7(30):47998-48010. PubMed ID: 27384992
    [Abstract] [Full Text] [Related]

  • 10. Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer.
    Bao R, Lai CJ, Wang DG, Qu H, Yin L, Zifcak B, Tao X, Wang J, Atoyan R, Samson M, Forrester J, Xu GX, DellaRocca S, Borek M, Zhai HX, Cai X, Qian C.
    Mol Cancer Ther; 2009 Dec 26; 8(12):3296-306. PubMed ID: 19952121
    [Abstract] [Full Text] [Related]

  • 11. Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression.
    Li H, Takayama K, Wang S, Shiraishi Y, Gotanda K, Harada T, Furuyama K, Iwama E, Ieiri I, Okamoto I, Nakanishi Y.
    Cancer Chemother Pharmacol; 2014 Dec 26; 74(6):1297-305. PubMed ID: 25344762
    [Abstract] [Full Text] [Related]

  • 12. The autophagy inhibitor chloroquine overcomes the innate resistance of wild-type EGFR non-small-cell lung cancer cells to erlotinib.
    Zou Y, Ling YH, Sironi J, Schwartz EL, Perez-Soler R, Piperdi B.
    J Thorac Oncol; 2013 Jun 26; 8(6):693-702. PubMed ID: 23575415
    [Abstract] [Full Text] [Related]

  • 13. Synergistic action by multi-targeting compounds produces a potent compound combination for human NSCLC both in vitro and in vivo.
    Zhang C, Zhai S, Li X, Zhang Q, Wu L, Liu Y, Jiang C, Zhou H, Li F, Zhang S, Su G, Zhang B, Yan B.
    Cell Death Dis; 2014 Mar 20; 5(3):e1138. PubMed ID: 24651441
    [Abstract] [Full Text] [Related]

  • 14. Curcumin lowers erlotinib resistance in non-small cell lung carcinoma cells with mutated EGF receptor.
    Li S, Liu Z, Zhu F, Fan X, Wu X, Zhao H, Jiang L.
    Oncol Res; 2013 Mar 20; 21(3):137-44. PubMed ID: 24512728
    [Abstract] [Full Text] [Related]

  • 15. 3,6,2',4',5'-Pentahydroxyflavone, an orally bioavailable multiple protein kinase inhibitor, overcomes gefitinib resistance in non-small cell lung cancer.
    Sheng Y, Li W, Zhu F, Liu K, Chen H, Yao K, Reddy K, Lim DY, Oi N, Li H, Peng C, Ma WY, Bode AM, Dong Z, Dong Z.
    J Biol Chem; 2014 Oct 10; 289(41):28192-201. PubMed ID: 25122774
    [Abstract] [Full Text] [Related]

  • 16. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
    Shou J, You L, Yao J, Xie J, Jing J, Jing Z, Jiang L, Sui X, Pan H, Han W.
    Cancer Lett; 2016 Aug 28; 379(1):124-33. PubMed ID: 27264264
    [Abstract] [Full Text] [Related]

  • 17. Phenethyl isothiocyanate synergistically induces apoptosis with Gefitinib in non-small cell lung cancer cells via endoplasmic reticulum stress-mediated degradation of Mcl-1.
    Zhang Q, Chen M, Cao L, Ren Y, Guo X, Wu X, Xu K.
    Mol Carcinog; 2020 Jun 28; 59(6):590-603. PubMed ID: 32189414
    [Abstract] [Full Text] [Related]

  • 18. Sensitization of lung cancer cells to cisplatin by β-elemene is mediated through blockade of cell cycle progression: antitumor efficacies of β-elemene and its synthetic analogs.
    Li QQ, Wang G, Huang F, Li JM, Cuff CF, Reed E.
    Med Oncol; 2013 Mar 28; 30(1):488. PubMed ID: 23397083
    [Abstract] [Full Text] [Related]

  • 19. Picropodophyllin causes mitotic arrest and catastrophe by depolymerizing microtubules via insulin-like growth factor-1 receptor-independent mechanism.
    Waraky A, Akopyan K, Parrow V, Strömberg T, Axelson M, Abrahmsén L, Lindqvist A, Larsson O, Aleem E.
    Oncotarget; 2014 Sep 30; 5(18):8379-92. PubMed ID: 25268741
    [Abstract] [Full Text] [Related]

  • 20. Longikaurin A, a natural ent-kaurane, induces G2/M phase arrest via downregulation of Skp2 and apoptosis induction through ROS/JNK/c-Jun pathway in hepatocellular carcinoma cells.
    Liao YJ, Bai HY, Li ZH, Zou J, Chen JW, Zheng F, Zhang JX, Mai SJ, Zeng MS, Sun HD, Pu JX, Xie D.
    Cell Death Dis; 2014 Mar 20; 5(3):e1137. PubMed ID: 24651440
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.